Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
Caliper Life Sciences, Inc. (Nasdaq: CALP) and Affymetrix, Inc. (Nasdaq: AFFX) today announced that Caliper has issued Affymetrix a non-exclusive license to use a portion of Caliper's microfluidics patent estate with Affymetrix' GeneChip(R) microarray technologies. The license extends to the manufacture and sale of GeneChip brand products in all areas of application, including research, diagnosti...Columbia University licenses next-generation DNA sequencing technology
Columbia University announces today that it recently executed an exclusive license agreement for a next generation DNA sequencing technology to Intelligent Bio-Systems (IBS), Inc. This innovative DNA-sequencing technology was invented by Dr. Jingyue Ju, professor of Chemical Engineering and head of DNA Sequencing and Chemical Biology at the Judith P. Sulzberger, M.D. Columbia Genome Center at Col...GenTel licenses next generation cancer research
In the serum of pancreatic cancer patients...Third Wave licenses Innogenetics tech to settle lawsuit
The two companies' relationship goes back further. In Aril 2004 Third Wave forged a deal under which Innogenetics was an exclusive distributor...WARF licenses patents for new glaucoma drug treatment
The patents are based on research conducted by <a target="blank" href="http://www.wisc.edu/kaufmanla...PKWARE Licenses Technology to Expand SecureZIP Standard
Brown Deere, Wis. - PKWARE, a software developer based in Brown Deer, Wisconsin, has announced a set of software licensing initiatives designed to expand the availability of the companys new SecureZIP technology. Responding to industry feedback PKWARE decided to license its SecureZIP technology to other vendors including , which...Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
MADISON, Wis. - The a California-based publicly traded company (NYSE: MNT), which gives Mentor the exclusive manufacturing and marketing rights to the proprietary botulinum...US Government Licenses New Hypertension Drug
The US Government has licensed Sildenafil to trade under the name Revatio for treating pulmonary hypertension. The University Hospital in Giessen’s pulmonary hypertension// specialist Ardeschir Ghofrani has revealed that Sildenafil is the first drug that can be administered as a pill that has a positive effect in the lung's vessels. “It broadens the right vessels, helps good aeration and...Panacea Biotec In-Licenses FMD Vaccine
Panacea Biotec Ltd today said it has entered into an agreement with the National Research Development Corporation (NRDC) // for in-licensing of Foot and Mouth Disease (FMD) vaccine developed by the Indian Veterinary Research Institute. 'As part of the agreement, we will produce and market the vaccine in the Indian market first. As and when we meet the requirements of the domestic marke...Thailand Goes Ahead With Licenses for Generic Drugs
Thailand has okayed the issue of compulsory licenses for inexpensive versions of heart disease and AIDS drugs,// a move, not likely to sit well with pharmaceutical bigwigs. Health Minister, Mongkol Songkhla, confirmed that the laws are in place and are effective. According to the Health Minister, the drugs are meant for treating HIV-AIDS and heart disease. He did not elaborate on whet...Swedish Biotech Licenses HIV Drug to China for Development
The Swedish biotechnology company Medivir announced yesterday that it has licensed its experimental non-nucleoside// reverse transcriptase inhibitor (NNRTI), code-named MIV-160, to the Chinese company Guangdong Lantai Viewland Pharmaceutical for the China region. Medivir will retain the worldwide rights to the product. Guangdong Lantai Viewland Pharmaceutical will potentially develop...More Foreign Trained Doctors Receive Licenses
A recent report has shown the increase in the number of licenses issued to foreign-trained doctors by the Ontario College of Physicians// and Surgeons- 42 per cent of the 2,961 new licenses have been given to internationally trained medical graduates. Among the foreign-trained doctors who received licenses, only one-third received certification for medical practice, while the rest wer...Materia Licenses Metathesis Catalyst Platform to Eisai
PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, Inc., acatalyst technology company, announced today the licensing of itsmetathesis platform to Eisai Co., Ltd., a leading Japanesepharmaceutical company, for use in drug discovery and development.The non-exclusive license agreement provides rights to discover,develop, and patent pharmaceutical compounds and related processesusing th...